Autoimmunity BioSolutions
Genetically guided therapies targeting elevated soluble IL7 receptor levels in autoimmune disease.
$1MSeed extension
Role not disclosedIC
Independent Capital
Activity from announced rounds
Activity in this selectionUnited States · May 31, 2026 · May 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $1M 1 disclosed · full round size, not this investor’s share